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CHAPTER 24 
Recent Developments in Alternatives to 
Animal Testing 
Katy Taylor 
Director of Science and Regulatory Affairs, Cruelty Free International 
(formerly BUAV) and the European Coalition to End Animal Experiments, 
London, United Kingdom 
1 Introduction to Alternative Methods 
At least 115 million animals are thought to be used for scientific purposes every 
year, worldwide (Taylor et al., 2008). Animals are typically used to test whether 
an intervention will cause harm to humans or other animals of the same or 
different species, i.e. safety testing; or whether it will work, i.e. efficacy test­
ing. Interventions can include testing substances (such as cosmetic products, 
industrial chemicals, drugs, pesticides, food additives, and biocides ); medical 
devices; surgical techniques; environmental changes; or other ways of altering 
the physiology and/or behavior of a live animal. Safety testing is highly regu­
lated and is often done after any efficacy testing, if necessary, to finally check 
that an intervention is safe for humans and/or other animals to use. Efficacy 
testing is less formalized and often occurs in universities as ideas are tested in 
live animals as a "proof of concept", often prior to the development of actual 
interventions to help humans or other animals. 
Methods that replace techniques that use live animals, or methods of test­
ing substances without live animal use, are known as alternatives, replacements 
or non-animal methods. Some prefer the term advanced technologies given the 
fact that they often rely on more sophisticated technology and are more hu­
man-relevant than the animal test they replace (see Langley et al., 2015). There 
have been efforts to replace animal tests since the 1960s. Significant progress 
initially came in replacing animals used to diagnose human disease; to produce 
biological drugs ( such as vaccines); and to safety test batches of these drugs 
as they were produced. Concerns about safety were the initial driver for this, 
as drugs produced using animal material could be contaminated with animal 
diseases. However, cost, efficiency, and the need for swifter and more accurate 
predictions also played a part. Some of the earliest replacements are, in fact, no 
longer referred to as such, as they are now standard practice. For example, the 
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polio vaccine used to be produced in primary monkey kidney cells, resulting in 
the death of tens of thousands of monkeys every year. However, by the 1970s, 
the use of long-lived human or monkey cells in culture was common place 
and the risk of contamination with animal viruses was also eliminated 
(Bookchin and Schumacher, 2005). Batches of the vaccine against yellow fever 
used to be tested for efficacy (potency) on animals in lethal dose tests, but 
these tests were replaced by a cell culture test, the plaque-reduction neutral­
ization test, in the 1970s (World Health Organization, WHO, 2007). 
As analytical techniques improved, as well as scientific understanding, 
animals were no longer used as indicators of disease because disease-causing 
agents were now both understood and could be measured directly. For example, 
every batch of insulin used to be checked using 600 mice and tens of thousands 
were used in the United Kingdom alone every year. The mouse convulsion test 
was a particularly unpleasant test, as the number of mice that went into con­
vulsions following injection was used as a measure of the strength of vials of 
insulin. Now, analytical methods can measure the components of insulin di­
rectly (Underhill et al., 1994). Similarly, rabbits were used in the diagnosis of 
pregnancy. A rabbit was injected with the urine from a potentially pregnant 
woman, and if the rabbit's ovaries swelled (detected upon killing and dissect­
ing the rabbit), this was considered a good predictor of pregnancy (Friedman, 
1939). Now, of course, we know that the substance indicative of pregnancy is 
gonadotrophin, which can be detected directly using chemical tests. 
Nowadays, alternative methods can include a range of techniques, including 
cell-based tests ( in vitro); tests using tissue taken from dead humans or animals 
( ex vivo); chemical-based analytical tests ( in chemico ); computer-based model­
ling (in silico); and ethical human studies (in vivo). Using examples of these 
types of methods used for regulatory safety testing, this chapter illustrates the 
difficulties seen in replacing animals and how they can be overcome. 
2 Recent Developments in Alternatives to Toxicity Testing 
The past 30 years have seen a dramatic increase in the development of alterna­
tives to animals (see Liebsch et al., 2011). Advances in replacements are more 
recognized in the field of toxicology because it is this area that has received the 
most attention. Regulatory, typically toxicity testing, is only a small proportion 
of the global testing on animals (8% in Europe according to Daneshian et al., 
2015); but due to the standardized nature of the tests, replacement of just one 
test has a permanent effect on the use of animals in that area and is, therefore, 
seen as particularly worthwhile. 
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Table 24.1 outlines the status of alternatives for the most common tests 
used for chemical safety testing, which traditionally and in most cases still use 
animals. Two things stand out in this table. First, that replacement of topical 
endpoints (i.e., tests that measure effects on the external parts of the body) 
are almost completely replaced. However, alternative tests for systemic, broad 
effects, such as repeated dose, do not yet feature in the regulatory acceptance 
column. Second, there has been significant progress in the past 10 years in reg­
ulatory acceptance. Many tests have gained approval from the Organisation for 
Economic Co-operation and Development ( OECD ), even if they can only be 
used in combination with other tests. 
TABLE 24.1 Alternatives for standard toxicity tests for chemical safety 
Endpoint Animal test Alternative tests Regulatory 
Skin The substance is rubbed 
absorption onto the shaved backs of 
rats, and they are killed 
the next day ( OECD TG 
427). 
Acute Rats are exposed to a 
toxicity very high dose of the 
substance, such that 
a number of them 
are expected to die 
( OECD TG 402,403, 
420,423,425,436). 
Skin Substance is rubbed onto 
irritation/ the shaved backs of rah-
corrosion bits, and they are killed 
2 weeks later ( OECD TG 
404). 
Eye Substance is placed into 
irritation/ the eyes of live rabbits 
corrosion who are monitored for 
up to 3 weeks ( OECD TG 
405). 
acceptance 
Ex vivo skin-based tests that OECD TG 428 
measure the amount of ( 2004 ). Standalone 
substance that passes through replacement. 
excised skin. 
Cell-based tests, in particular Not formally ac-
the NRU 3T3, which measures cepted, can be used 
the extent of cell death in the in combination with 
presence of the substance. other information 
only. 
Reconstituted in vitro human OECD TG 431 (2004) 
skin models that measure and 439 (2010), plus 
the extent of cell death in the others. Testing strat-
presence of the substance. egy accepted ( OE c D, 
2014a). 
Excised eyes from hens and OECD TG 437 and 
cattle killed for food ( ex vivo) 438 ( ex vivo, 2009 ); 
can detect non-irritants and OECD TG 492 (HCE, 
severe irritants; human cor- 2015). Testing strate-
neal epithelial (HcE) models gies yet to be formally 
based on excised human skin accepted. 
or corneas that measure the 
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Animal test Alternative tests Regulatory 
acceptance 
extent of cell death in the 
presence of the substance can 
detect non-irritants. 
The substance is rubbed Several tests exist that cover OECD TG 442c 
onto the shaved skin the adverse outcome pathway (DPRA, 2015); 442d 
of guinea pigs who are (AOP) for skin allergy. The (keratinocyte assay, 
subjectively assessed for direct peptide reactivity assay 2015); and 442e (h-
allergy (Buehler or the (DPRA) measures the binding CLAT, 2016). Testing 
guinea pig maximiza- of the substance to proteins strategies yet to be 
tion test, GPMT; OECD (in chemico); and the formally accepted. 
TG 406); or painted onto in vitro keratinocyte assay and 
the ears of mice who the human Cell Line Activa-
are killed 6 days later to tion Test (h-CLAT), which are 
assess the immune re- based on human skin cells, 
sponse (local lymph node measure part of the immune 
assay, LLNA test), (OECD 
TG 429, 442a/b ). 
The substance is force-
fed or injected into mice 
or rats for 14 days; they 
are then killed to look at 
the effects on their cells 
(OECD TG 474,475,483, 
486, 488, 489 ). 
Rats ( occasionally 
rabbits, mice, or dogs) 
are force-fed, forced to 
inhale, or have the sub-
stance rubbed onto their 
shaved skin every day 
for 28 or go days, before 
being killed (oECD TGs 
407-413). 
response. 
Several in vitro tests, including OECD TG 471 (1997); 
bacteria (Ames) tests, in vitro 473 (1997); 476 
chromosome aberration, cell (1997); 487 (2010); 
micronucleus, and gene muta- 490 (2015). Positive 
tion tests are available. results, however still 
A battery of two or three cell- lead to follow up in 
based tests is always carried vivo. 
out before conducting an 
animal test. 
In silico techniques, such as Read across is ac-
read across, can be used if the cepted on a case-by-
substance is similar to existing case basis (see OECD, 
ones that have already been 2014b ); battery of 
tested. in vitro tests or lab 
A battery of in vitro tests or lab on a chip are not yet 
on a chip models are still in accepted. 
the development phase. 
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Carcinoge­
nicity 
Rats or mice are fed the 
substance for two years 
to see if they get cancer 
(OECD TG 451,452). 
Cell transformation assays 
( CTA) based on cellular 
changes to rodent cells have 
been in use for 50 years and 
CTA assays have failed 
to gain international 
regulatory acceptance 
and are used for 
can detect go% of known hu- screening purposes 
man carcinogens. only (oECD 2015, 
2016). 
Reproductive Pregnant female rabbits In silica techniques, such as Read across is ac-
toxicity or rats are force-fed the read across, can be used if the cepted on a case-by­
substance and then killed substance is similar to existing case basis (see OECD, 
along with their unborn ones that have already been 2014b ). EST has 
babies (oECD TG 414). tested.The in vitro Embryonic failed to gain inter­
Stem cell (EST) test is based on national regulatory 
mouse stem cells. Substances 
are classed as toxic if they 
block development into beat­
ing heart cells. 
Other in vitro tests are still in 
the development phase. 
Receptor binding assays are 
in vitro assays that can detect 
activation of genes involved in 
hormone production. 
acceptance. Receptor 
binding assays ( OECD 
TG 455, 2012; 457, 
2012; 456, 2oll) are 
accepted to screen for 
potential endocrine 
disrupting properties. 
For a list of all OECD Test Guidelines referred to in this table, see http://www.oecd.org/chemica­
lsafety /testing/ oecdguidelinesforthetestingofchemicals.htm. 
It is widely acknowledged that public pressure has played a significant part in 
encouraging these developments. Public outrage at animal testing for cosmet­
ics started in the 1970s and gained momentum in the 1980s. In Europe, the out­
cry turned into calls for an actual ban on cosmetics testing on animals, even in 
the absence of alternatives for all relevant animal tests. From 1993, and finally 
ending in 2013, a series of deadlines were negotiated and re-negotiated within 
the European Union (Eu) by which the testing had to end, first for the testing 
of products and then for the testing of ingredients (European Commission, 
2017 ). During this period, the cosmetics industry foresaw that testing any new 
substances on animals would soon have to end, and they invested in alterna­
tives, as did the European Commission (Ee). 
The formal encouragement to use alternatives in the EU was set in stone 
by the Eu Directive on animal testing in 1986 ( Council of the European 
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Communities, 1986, Directive 1986/609/EEC) and revised in 2010 (European 
Parliament, 2010, to Directive 2010/63/EU). Directive 2010/63/EU states that an 
animal test must not be conducted if an alternative method is available. This 
rule is unique to the EU; and while not enforced as well as one might hope, 
it has nonetheless helped encourage the promotion of alternatives interna­
tionally. Finally, the overhaul of EU chemicals' legislation in 2006 also played 
a part in driving the need for alternative methods. The new chemical regu­
lation, Registration, Evaluation, Authorisation and Restriction of CHemicals 
(REACH) is interesting in that it requires the testing of all new and existing 
chemicals on animals, unless alternative methods or data already exist (Eu­
ropean Parliament and the Council of the European Union, 2006, Regulation 
1907 /2006). The fact that this could result in the use of up to 38 million animals 
(Joint Research Centre, 2006), has encouraged both regulators and industry to 
look for alternatives to keep costs and animal numbers down. 
3 Implementation of Alternative Methods 
The replacement of an animal test is a laborious and lengthy, scientific and bu­
reaucratic process. Figure 24.1 outlines the steps that typically need to be taken 
before an animal test can be finally considered replaced by another method. 
Unfortunately, the outlined process is often repeated for each sector of use. For 
example, the method needs to be validated and accepted for replacing animals 
to test chemicals and then repeated in order for the method to be considered 
acceptable to replace animals used in drug testing. This is because the types of 
chemicals differ in each sector, and there is a fear that the alternative may not 
work on different chemistries. There is also an element of distrust in alterna­
tives not developed for that sector, and so the industry tends to want to re­
evaluate the alternative itself rather than transfer it across immediately. 
Development is the stage in which the alternative is created, optimized, and 
initially tested. Academe plays a large role at this stage. Alternative centers, 
such as the UK National Centre for the 3Rs and alternatives charities, are vital 
in funding this kind of work. Researchers may develop spin-off companies to 
further develop a method. Larger chemical, medical, and cosmetics companies 






FIGURE 24.I The process of acceptance of an alternative test method. Steps in black are 
primarily science driven, steps in white are primarily regulatory driven. 
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may also develop alternatives, even creating their own spin-off companies or 
buying existing ones. For example, L'Oreal purchased the rights to EpiSkin in 
1997 and bought the SkinEthic company in 2006, so that they could develop 
and use their own human skin irritation models (Auplat, 2012). Unfortunately, 
academics may be satisfied by the publication of their method in scientific 
journals and often leave it to others to ensure it is used more widely. More pro­
active, academic-driven development may still struggle to grasp the regulatory 
hurdles that need to be overcome before the method can be used. Unfortunate­
ly, industry-driven development can also be rather inward looking. Companies 
may be satisfied if the method is considered suitable for their own in-house 
purposes for screening substances; and, often, they have little incentive to do­
nate the method to the wider community, particularly if they have invested 
heavily in its development, and competitors could gain from its use. 
Validation is the stage in which the method is independently assessed to en­
sure it is reliable and accurate. This step is vital if the method is to progress to 
acceptance. There are internationally agreed principles for the way a method 
should be validated; but they are rather vague and not always well understood. 
The key requirements include, showing that the method produces the same 
results when tested at different times in the same laboratory and when used 
by other naive laboratories, and that the results are consistent with what is 
expected, i.e. the test does what it is designed to do. The process is laborious, 
requires collaboration between several laboratories, and can be expensive. If 
things go wrong, the validation stage may have to be repeated. In most cases, 
historical animal test data is used as the gold standard by which an alterna­
tive method is assessed, so no new animal tests have to be done; but there can 
be problems in ensuring the old animal data is of good quality. Quite often, 
the fact that the animal test itself was never validated causes problems dur­
ing validation, as the assessors realize that the animal data is so unreliable or 
inaccurate that they cannot trust it (Balls, 2006). Species differences also play 
a significant role in making comparisons between human-based cell tests and 
animal test results very difficult (Hartung, 2007 ). 
Official bodies are seen as a good way of ensuring a method is correctly vali­
dated. In Europe, the European Commission's European Centre for the Valida­
tion of Alternative Methods (ECVAM) is an important validation body. There 
are now equivalent bodies in other countries, such as the United States (us) 
(Interagency Coordinating Committee on the Validation of Alternative Meth­
ods, ICCVAM ), and Japan (Japanese Centre for the Validation of Alternative 
Methods, JaCVAM). Unfortunately, the process of validation and regulatory 
acceptance is still a bit of a black box. Methods do not have to go through 
these validation centers to be accepted, but it often helps. Companies with 
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new methods are often unsure about the process, whether they need to submit 
their method for official validation or directly to the regulatory body, who they 
should contact, and what information they need to provide. 
Formal test method. Once there is sufficient evidence that an alterna­
tive method is valid, the next stage is to write up how the method should be 
performed as a formal test method. In Europe, the policy is to gain wider agree­
ment on the method via large international collaborations, such as the OECD 
or the International Council on Harmonization ( I c H ). This is so that the meth­
od, in theory, will be accepted outside Europe and European companies will 
not be disadvantaged by having to conduct other tests. Negotiating how to con­
duct the method is often combined with further analysis of the validity of the 
method and can take several years. This stage can also provide false hope that 
a method is acceptable in all regions; this is because, although an agreement 
may be sought in principle, at an international level, the regional acceptance 
process can be prolonged as regulators still have to decide that the method is 
relevant and acceptable to the legal framework in their region. 
Regulatory acceptance does not automatically happen following the publi­
cation of a formal test method, a fact that is often not widely appreciated. Fol­
lowing adoption of a formal test method, typically several regional regulatory 
agencies have to assess independently whether the method can be used for 
their sector ( e.g., chemical, medicines, or cosmetics). Unfortunately, there is of­
ten no official mandate for them to do this, and they may need political pressure 
to act. Regulators do not have to wait until the method is formally recognized 
internationally to decide whether they will accept it for their purposes, but they 
frequently do. Negotiations within each regulatory body can take many months, 
or even years; and currently, these have to happen separately for each sector 
and region. Regulators typically accept methods by updating their guidelines, 
but it is often only when a corresponding legislation is changed that industry 
becomes aware of the need to use the alternative in place of the animal test. 
Deletion of the animal test. Changing sector specific legislation to replace 
any requirement for a specific animal test with the alternative takes several 
years and the process is usually not started until the very end of the process. 
Political pressure is usually needed to instigate the deletion of the animal 
test, often following pressure from animal protection organizations. For ex­
ample, there was a delay of seven years from the point in which there was a 
formal method alternative to the rabbit skin irritation test ( Commission of the 
European Communities, 2009) until the rabbit test was deleted from REACH 
requirements and replaced with the skin irritation methods (European Com­
mission, 2016a). The process was not initiated until 2012, following a complaint 
from Cruelty Free International. To date, the rabbit test is still performed in 
Europe and elsewhere, and the formal test method for the rabbit test ( OECD 
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TG 404) still exists. The only standard regulatory animal test that has been de­
leted from OECD requirements is the LD50 acute toxicity test ( OECD, TG 401) 
in 2001, which was "replaced" by other animal tests that cause slightly less suf­
fering or equivalent suffering to fewer animals. 
Regulatory acceptance is not usually required for methods that replace ani­
mals in basic research conducted in academe. Here, the route to acceptance is 
a less defined, unofficial, and often very slow process. The scientific communi­
ty may gradually move towards alternative methods, usually through the com­
mon scientific channels of publications, conferences, and workshops. There is 
no body within the medical research establishment tasked with coordinating 
this process, although national 3R centers may facilitate more rapid progress 
on a case-by-case basis. Regulators of animal experiments could play a role in 
ensuring that no animal-based projects are conducted in their region if there 
is an alternative; but as the line between what is and what is not an accepted 
alternative is less clear for basic research, they currently do not appear to do so. 
In summary, the development and validation stages are primarily science­
dependent processes, which can be sped up through appropriate funding and 
coordination. The stages of formal test method, regulatory acceptance, and dele­
tion of the animal tests are primarily regulation dependent and can be acceler­
ated by political will and regulatory enforcement. 
4 The Future of Alternatives 
The difficulties of replacing animal tests, combined with increasing frustra­
tion with the lack of reliability of animal tests, have forced scientists, in recent 
years, to consider whether a paradigm shift is needed. A ground-breaking re­
port to this effect was published by the National Academy of Sciences (NAS) 
in the us in 2007. Rather than criticizing the ethics of testing on animals, the 
report focused on better science and set out a future vision for toxicity testing. 
The idea is that society should move away from using black box animal models, 
where tests depend on simply counting how many animals die rather than on 
understanding why they die. Instead, toxicology should seek to map human 
reactions at a more molecular and cellular level, something entirely possible 
in vitro. The Toxicology Testing in the 21st Century (ToX21) concept was funded 
on a practical level by the us government under the ToxCast project, which is 
screening thousands of chemicals using simple in vitro tests to help start the 
process of identifying toxicity pathways (Richard et al., 2016). 
The NAS report has helped accelerate the concept of Adverse Outcome 
Pathways (AOPs) which provides the biological explanation for a single toxic 
event. Some toxic events, such as skin irritation and skin sensitization, may 
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only have one biological explanation. For example, the AOP for skin sensitiza­
tion has been described (OECD, 2012) and is made up of four steps: reaction 
of the substance with proteins in the skin, inflammatory responses in kerati­
nocyte skin cells, activation of dendritic cells, and lastly the proliferation of T­
cells. The first three steps now have OECD approved in chemico or in vitro tests 
(see Table 24.1) ; the fourth step is measured in the mouse LLNA. 
Unfortunately, some animal tests capture many different types of toxicity, 
including some that are not relevant to humans. For example, repeated dose 
toxicity tests assess long term toxicity, which can manifest in a number of ways 
( e.g. cancer, liver disease, and heart disease, among others). To replace animals 
for these tests will require the identification of many AOPs and the develop­
ment of tests for the steps within them. The thinking is that if all possible AOPs 
relevant to repeated dose toxicity can be mapped, then in chemico or in silico 
tests for only some of the key steps will need to be created. The risk is that find­
ing all of these AOPs will take time, and animal tests will not be replaced until 
that happens. Nonetheless, the concept has now taken hold in Europe, and the 
OECD is supporting the population of a database of AOPs ( OECD, n.d.). 
Another development in toxicology that seeks to overcome the criticism 
that cell cultures are too simplistic, is the lab on a chip concept: body or organ 
on a chip models vary in size and complexity but essentially use engineering 
technology to combine small cultures of cells ( e.g., liver, brain, and kidney) 
into a single, tiny device with fluid running between the compartments of 
each type of cell. The idea is to recreate some of the key organs and processes 
that occur within a human on a miniature scale (Marx et al., 2012 ) . The concept 
is proving not as easy as it seems though, with issues regarding how to remove 
waste products, how to keep cells alive, and how to mimic realistic pressures 
within the fluidic channels. The lab on a chip and/or the AOP approach will 
also likely lead to the replacement of animal models for basic research (Lang­
ley et al., 2017 ) . In a way, it should be easier to replace animal tests for drug 
development, since drug discovery itself is already very reductionist. New 
drugs are usually developed to interact with cell-based mechanisms inside the 
body that trigger disease. This is similar to the AOP approach, and it should 
be possible to model it in vitro. It is, therefore, rather incomprehensible that 
researchers look to a more holistic, whole animal approach to demonstrate 
both the efficacy and safety of a new drug, with all the added complications 
of lack of relevance and species differences that this brings. Encouraging 
researchers to justify efficacy based on human cell-based approaches and then 
testing the drug on a few patients in, so called futiliry trials ( see Crean or et al., 
2015, for example of a futility trial), could be one approach to speed up drug 
development and reduce the high number of drugs that fail in clinical trials. 
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Another approach is to use technology to enable humans to be used safely 
in studies that would otherwise use animals in a harmful manner. Microdos­
ing exploits the technological advances in analytical techniques to enable 
volunteers to be injected with novel substances at such low levels, that even 
potentially harmful substances do not to pose a threat (Lappin, 2015) . Simi­
larly, improvements in brain imaging technology are enabling researchers to 
measure human brain activity non-invasively, and at a high level of precision, 
so that invasive tests in monkeys will soon be considered redundant (Bailey 
and Taylor, 2016). 
5 Barriers to the Implementation of Alternatives and How to 
Overcome Them 
5.1 The Current Scientific Paradigm 
A major stumbling block when it comes to replacing animals is the current way 
that hypotheses are tested in science. Figure 24.2 outlines the typical process 
scientists go through when testing either the safety or efficacy of a substance, 
or indeed any hypothesis. The process is one of testing in models of increasing 
complexity with growing confidence in the hypothesis, as it successfully passes 
each hurdle. 
The most common justification for using animals is the apparent need to 
test a substance or idea in a "complex, whole being" before there is enough 
confidence that it can be tested safely in humans. The assumption behind this 
is that the complex, whole being will capture all possible, unforeseen ways in 
which the substance or idea could be harmful ( or not work), avoiding harm 
to ( or wasting time on) human volunteers. This "complexity" argument is 
one reason for the lack of support for in vitro based techniques, as these are 
seen as less complex and, therefore, inferior. The desire to capture all possible 
interactions appears to override the very real possibility that many of these 
interactions are wrong by the very nature of testing in the wrong species. This 
is very frustrating for those who support alternative approaches; and there ap­
pears to be a real gap between the two groups in terms of what is more impor­
tant, complexity or relevance. Added to that is the fact that demonstration of 
-
Test in a simple 
model (computer/ in 
vitro /DNA screening). 
Test in more 
complex model 
(animal) 
FIGURE 24 .2  The standard approach to testing medical hypotheses. Confidence increases as 
you move from left to right. 
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the predictivity of alternative methods often fails to convince those who can­
not get past the fact that the alternative is simply not a live, complex animal. 
If an alternative method is found to be go% predictive of effects in humans, 
this does not seem to provide confidence. The answer is always, "what if?" This 
caution has undoubtedly raised the standard by which alternative methods 
are measured; but some believe that the bar is, in fact, now too high and is still 
being unfairly applied. 
The complexity versus relevance debate may be resolved by greater under­
standing and uptake of the AOP approach. This approach seeks to break down 
the complexity of biological processes on a more scientific basis. Alternative 
methods can be chosen that measure a distinct part of a mechanistic process 
that leads to an adverse effect (i.e., toxicity). Using an alternative method that 
is known to predict even just one step in the AOP should give confidence that 
it is relevant. Combining several methods that test different parts of the AOP 
should also help address the complexity issue. Lab on a chip methods, as well 
as more complex in vitro methods, such as 3D tissue constructs and mini-brains 
( see Caruso, 2017 ), are also another solution to increase both relevance and 
complexity. 
5.2 Interface with Legislation 
Scientists developing alternative methods have historically designed them 
to give simple answers to the question, is the substance being tested safe or 
toxic, yes or no? This was seen as a good first step to assist in their valida­
tion and initial adoption, even if the animal test they are designed to replace 
actually produces quantitative (numerical) answers on the extent of toxicity. 
However, failure of alternative methods to produce equivalent results to the 
animal tests has been one reason for the delay to their full implementa­
tion. For example, the in vitro skin irritation/corrosion methods were initially 
validated to give a yes/no result on whether a substance would cause skin 
corrosion in 1998 (ECVAM Scientific Advisory Committee, ESAC, 1998). This 
limited their use because chemical sector regulators actually required these 
methods to present the result as not i"itant, i"itant, or severely i"itant/ 
co"osive. This is because the results of the animal test are used not only for 
risk management purposes but for classification and labelling of substances, 
which is governed by different legislation. It was not until 2007 that a slightly 
different protocol, using the same skin methods, was validated to provide 
this information on irritation (ESAC, 2007). Even then, it was not until 2009 
(ESAC, 2009)-when a third, more rapid validation was completed because 
the classification and labelling requirements had changed since the start of 
the process-that the rabbit test was finally replaced using a combination 
of two methods. 
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Since the issue surrounding the validation of the skin irritation methods, 
there is now greater recognition of the need to be aware of classification and 
labelling requirements, but problems still occur. For example, the in vitro skin 
sensitization methods were also validated to provide yes/no answers; but the 
regulators require three answers: no effect, weak effect, or strong sensitizing. It 
was for this reason that the E C  and Member States recently refused to remove 
the mouse LLNA test from REAC H requirements, as they are of the opinion that 
full replacement for classification and labelling is not yet possible using the in 
vitro methods (European Commission, 2016b ). 
The issue is further complicated by countries around the world that have 
different requirements for the classification of substances based on the same 
toxicity test results. The alternatives are often only validated against one 
scheme. For chemicals, this is often the United Nations Globally Harmonized 
System (uN G HS) of Classification and Labelling of Chemicals, but this is not 
recognized by all countries and all legislations that may have different require­
ments. So, two additional hurdles are getting those involved in the validation 
of alternative methods to appreciate the regulatory use of the method and 
validate it accordingly and getting countries to harmonize their regulatory re­
quirements, irrespective of the methods used, to satisfy the requirements. Lack 
of international harmonization of classification and labelling requirements is 
one of the reasons why rabbit skin irritation tests are still being conducted in 
Europe for non-EU regulators, even though the alternatives are now accepted 
within Europe. 
5.3 Bureaucracy 
Bureaucracy plays a large part in the delay to the implementation of alter­
natives, in my view, particularly at the regulatory acceptance stage. Much of 
this bureaucracy could be avoided as illustrated below. It is, in my opinion, 
in part caused by inertia amongst regulators and a failure to incentivize and 
reward them for evaluating new methods. The process still largely relies on the 
goodwill of a few experts from a few countries. Industry are not specifically 
rewarded for developing alternatives and, indeed, run some risk if the alterna­
tive is not accepted ( due to wasted development costs). Regulators also run the 
risk of accepting a method that could fail in the real world, potentially causing 
harm to humans. Hiding behind bureaucratic delays avoids having to make a 
decision. 
There are bureaucratic delays caused by the desire to harmonize testing re­
quirements internationally. Harmonization is seen as a good thing, as it means 
that, in theory, a single (animal) test conducted in a laboratory in one country 
will be accepted for regulatory submission of that substance in all countries 
that sign on the agreement. This is called Mutual Acceptance of Data (MAD). 
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There have been tremendous efforts in the past 20 years to encourage the 
chemical and drug sectors to harmonize their requirements. As alternatives 
have been developed, they too have had to go through this harmonization pro­
cess. In theory, this is also a good thing, because once accepted no more animal 
tests would be required around the world for that specific substance. However, 
in reality the process of negotiation takes a long time; and to speed up the 
process, loopholes are placed in documents that can give a false sense that har­
monization has actually been achieved. A recent example is skin sensitization, 
where the alternative methods gained OECD acceptance relatively easily, but 
on the understanding that they cannot be used as standalone replacements. 
Therefore, there is no requirement for countries to accept these methods to 
replace the corresponding animal test, until perhaps another formal docu­
ment is agreed on at some point in the future that shows how they can be used 
together. 
In the EU the situation is further complicated. The EU defers to the OECD 
on the basis that international harmonization is preferable to EU acceptance 
(ignoring the fact that the EU is already a grouping of 28 countries). This causes 
on average two years' delay to a method that was validated in Europe. They 
then require that the test method, as agreed by the o E c D, be published in the 
official EU regulations (Commission of the European Communities, 2008, Test 
Methods Regulation EC440/2008,) in an almost completely bureaucratic pro­
cess that takes, on average, a further two to three years. For example, the first 
version of the reconstituted skin model was validated by ECVAM for detecting 
corrosive substances in 1998 (ESAC, 1998); but it was not adopted by the OECD 
until 2004 ( OECD, TG 431). The first version of the model for skin irritation 
was validated in 2007 (ESAC, 2007); but it was not adopted by the OECD until 
2010 (oECD TG 439). Due to political pressure at the time, the EU adopted an 
unusual procedure and accepted the skin methods before the OECD in 2000 for 
corrosion (European Parliament and the Council of the Eu, 2000 ), and in 2009 
for irritation (Commission of the European Communities, 2009). The EU has 
not done this since, even though similar delays have occurred for other meth­
ods. For example, the DPRA for skin sensitization was validated in 2012 (ESAC, 
2012); but it was not published as OECD TG 44C until 2015. Over two years after 
its publication in the OECD, it was published in the EU Test Methods Regula­
tion (Commission of the European Communities, 2017). 
One could argue that the bureaucratic delay between validation and regu­
latory acceptance gives industry time to advance their knowledge of the new 
methods, get them into place and gain confidence in their use. In reality, com­
panies, other than those directly involved in the development and validation 
of the new method, tend to remain unaware of these methods until they are 
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accepted. If they do become aware of them, they tend to wait for confirmation 
that they will be accepted, before investing in using them. One of the reasons 
for the delays at both the 0ECD and the Eu's Test Methods Regulation is the 
timing of the cycle for revising test guidelines. The process is annual at the 
0ECD; if you miss the deadline for submitting methods, you lose one year. Giv­
en sufficient political will, it should be entirely possible to speed up the process 
by increasing the cycle of meetings and, in Europe, by accepting that as most 
EU members are also members of the 0ECD, there is little need for a second 
round of negotiation to update the Test Methods Regulation. 
5.4 Lack of Funding 
Obtaining funds to develop replacements for animal tests is still very difficult, 
despite a few high profile, one-off, significant projects. For example, in response 
to the imminent cosmetics testing bans in 2009, the EC and the cosmetics in­
dustry each contributed €25 million towards the development of alternatives 
to animals for long-term toxicity testing (SEURAT-1, n.d.). Furthermore, the EC 
claims it has funded replacement methods in the last main scientific-funding 
stream, Framework Project 7 (2007-2013), to a total of €180 million (European 
Commission, 2013). However, compared to overall science funding, the levels 
of investment are relatively low. The total Framework Project 7 budget was 
€45.3 billion; as such, the Commission dedicated only 0.4°/o of its science bud­
get to alternatives to animal testing. 
National funding levels are even lower than central funding, perhaps reflect­
ing a general apathy about the need to improve the humanity and reliability of 
scientific methods. We recently compiled a survey of EU countries and found 
that direct funding of alternative (3Rs) methods was reported to total only 
€18.7 million in 2013 (Taylor, 2014). Only seven countries provided this funding: 
Austria, Belgium, Denmark, Finland, Germany, Sweden, and the UK. Much of 
this budget was dedicated to support national centers for the 3Rs rather than 
the development of new methods. Funding by the most generous country, the 
UK ( approximately €11 million), was still only 0.04°/o of its national science re­
search and development expenditure for that year. 
Central and national funding of alternatives, therefore, exists but is relative­
ly very low and ad hoc. This compares poorly to the funding given to equally 
ambitious big picture projects. For example, former us President Obama's proj­
ect to map the human brain was funded by us$100 million (The White House, 
President Barak Obama, n.d.); and the human genome project by us$3.8 bil­
lion (Human Genome Research Institute, n.d. ). However, these are single proj­
ects. Replacing all animal tests, even only in the field of regulatory toxicology 
comprises many, many projects. Clearly, the rate of change is likely to be slow 
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unless levels of funding significantly increase and are proportionate to the 
scale of the problem being addressed. 
5.5 Entrenchment 
Many of the remaining animal tests to be replaced, particularly for regulatory 
testing, have remained unchanged since they were first developed many de­
cades ago. For example, the pyrogenicity test in rabbits (used to establish if 
injectable drugs are contaminated) was developed in 1912 (Hort and Penfold, 
1912); the Draize skin irritation test on rabbits in 1944 (Draize et al., 1944); and 
the Buehler guinea pig skin sensitization test in 1965 (Buehler, 1965). 
Entrenchment is common in science (Kuhn, 1962 ). This may seem counter 
intuitive when one considers that what defines science is its questioning na­
ture. But even those who use animals in research will attest to the difficulty 
in getting funding for new approaches, as well as the difficulty in publishing 
research that uses a method that is different from the one everyone else is us­
ing. Behind closed doors, researchers will complain about journal editors even 
asking for their idea to be demonstrated in an animal model before they will 
publish it ( see Cronin, 2017; discussions at the recent EC conference on alterna­
tives). This situation is partly caused by the fact that those who are conduct­
ing research, reviewing papers, and reviewing funding applications are usually 
from within the same scientific peer group. New ideas that threaten the status 
quo can struggle to gain support; and researchers who are unhappy about their 
treatment are often afraid to speak up, in case it affects their university tenure 
or funding. 
Preferentially funding scientists who want to use different methods is a 
system that could work to promote change. However, apart from occasional 
large projects, such funding is still only taken on by specialist replacement 
charities with small budgets. Once they are a part of a project to replace 
animals, however, scientists can create a support network that can help to 
foster change; but it is crucial that funding is dependable for this to be sus­
tained. Another solution is finding a way to include fresh perspectives on the 
types of projects being funded. Including experts who are more motivated 
to challenge the need to test on animals in the ethical review of projects 
involving animals, such as individuals with expertise in alternatives or in 
animal protection, could have a big impact. Currently, funding and licens­
ing bodies only tend to include token lay persons in their discussions, who 
can feel out of depth and overwhelmed. Making applications or, at the very 
least, the funding policies of granting bodies open to regular public scrutiny 
could also help. 
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If improved funding of alternatives is the carrot, then enforcement is prob­
ably the stick. Although, most would say the carrot is the best approach for 
entrenched issues such as this, enforcement still has a role to play. In Europe, 
since 1986, it has been illegal, on paper, to conduct an animal test "if another 
scientifically satisfactory method of obtaining the result sought, not entailing 
the use of an animal, is reasonably and practicably available" ( Council of the 
European Communities, 1986, Directive 86/609/EEC). Unfortunately, in 2010 
this was watered down, to some extent, with a stricter onus being placed on 
methods that are "recognized under the legislation of the Union," although the 
general premise remains. "Member States shall ensure that, wherever possible, 
a scientifically satisfactory method or testing strategy, not entailing the use of 
live animals, shall be used instead of a procedure" (European Parliament, 2010 ). 
Technically the onus is on the Member State to not authorize animal tests 
where alternatives exist, rather than on the researcher. Our experience has 
shown, however, that if Member States can divest themselves of this, they will. 
Laboratories are granted multiple generic licenses that do not cover the specific 
substances being tested, which makes it impossible for the authorizing body 
to make decisions as to whether an alternative method is suitable. This is a 
particular issue with quality control tests, where the alternative can often be 
used for some substances and not others. Following an undercover investiga­
tion, Cruelty Free International recently demonstrated that a contract testing 
facility in the UK was testing substances for pyrogens on rabbits, for which 
the alternative bacterial endotoxin test was suitable, according to the Euro­
pean Pharmacopeia ( see Cruelty Free International, n.d. ). It was not until we 
challenged the UK competent authority that they began asking for substance­
specific information in advance (Animals in Science Regulation Unit, 2014). 
Enforcement of the use of alternatives for basic research is more complex 
and is currently being largely overlooked by regulators of animal experiments. 
Due to the myriad of ways in which animals can be used to test medical hy­
potheses, and the lack of formal standardized approaches, regulators tell us 
that they cannot really enforce the use of alternatives as they would for safety 
testing. Currently, in the UK, the onus is on the researcher, rather than the regu­
lator to demonstrate the absence of an alternative approach. The regulator, as­
sessing a potential project that intends to use animals, is not usually an expert 
in the area; and it is not clear to what extent researchers are really being chal­
lenged in their statements that alternatives are not available. The solution is 
for regulatory bodies to simply take responsibility for upholding the law when 
an alternative method is available that can prevent animal experiments or at 
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least partially replace them. Currently, some animal protection organizations 
see it as part of their role to hold regulators accountable to encourage them 
to do this. A better solution would be if a tougher stance was accepted inter­
nally by the regulators, perhaps as a consequence of a directive from their 
governments. 
6 Targets for Change 
It is clear from Table 24.1 that prior to the EU cosmetics testing bans, there was 
very little regulatory approval of alternative methods. There is a clear accel­
eration from 2003, the date of the implementation of the first testing ban ( for 
products). But now that Europe has a complete ban on cosmetics testing on 
animals, it is important that this momentum is not lost. It is possible that, with 
public support, new bans or deadlines could be put in place. There are already 
calls for bans on the testing of household products and all testing on dogs and 
monkeys. Using prohibitions on testing as an incentive for the development 
of alternatives is, however, hitting a hurdle in these areas. Animal testing for 
medical purposes is seen as something that cannot end until alternatives are 
available, and setting a timeline for science to replace animal experiments is 
not considered by some to be possible or even desirable. In a Nature survey of 
its readers ( over half of whom conducted animal experiments), 63% thought 
ending animal experiments was a desirable but unachievable goal (Ainsworth, 
2006). 
The absence of viable alternatives has, however, not hindered political agree­
ment in a number of other areas, where the ability to realize the promise relies 
to some extent on science and technology, such as the case of climate change. 
Internationally, the Kyoto Protocol was signed by 37 industrialist countries as 
well as Europe, in 1997, and set the goal of a 5% reduction in carbon emissions 
below 1990 levels by 2012. The target was met (United Nations Climate Change, 
n.d. ). Europe has a further commitment to reduce levels by 20% by 2020 (Eu­
ropean Commission, n.d. ). Although countries have signed up to reduce their 
emissions, no one is suggesting that they cease manufacturing cars or tum the 
power off in order to do so. Instead, goals to reduce in emissions are being met 
by increased efficiency and innovation (see European Commission, n.d.). One 
can see that a reduction in animal testing could also be achieved through more 
efficient use of animals ( e.g., not authorizing the more "blue sky" type of basic 
research and using less animals for any given purpose) and investment in tech­
nology. Setting a target of, for example, a reduction of 50% in national animal 
experiments by 2025 will enable countries to exert power over experiments 
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that they feel they could perhaps do without and to prioritize for replacement 
those that they cannot. Targets will feed into the ethical review committees 
for animal experiments, who will have to make harder decisions and actually 
reject some applications. Targets will also seep into the mindset of scientists, 
who will have to think more carefully about whether they are likely to be ac­
cepted before putting forward applications for new animal experiments. There 
will be more political will to fund alternatives and put in place the necessary 
governmental and institutional schemes to fund, develop, promote, and imple­
ment alternatives. 
It is important to remember that reduction in animal experimentation will 
not always rely on replacement. It is unfortunate that this view, however, pre­
vails even in Directive 2010/63/EU, which states that "this Directive represents 
an important step towards achieving the final goal of full replacement of pro­
cedures on live animals for scientific and educational purposes as soon as it 
is scientifically possible to do so" (European Parliament, 2010 ). In the area of 
basic research in particular, where the majority of animals are actually used 
(Daneshian et al., 2015), there is much more of an element of choice in con­
ducting an animal experiment. In a world with infinite questions about hu­
man biology, there are equally important questions that can be tackled that 
do not require resorting to animal experiments. Some scientists choose to use 
animals, but they could choose to study humans, or cells, or computer models 
and still contribute to the pool of medical knowledge. If we change the goal to 
one of improving the humanity and quality of medical knowledge, rather than 
replacing like for like, then, in my opinion, a significant proportion of animal 
research could end today. 
7 Conclusion 
The field of alternatives research has accelerated in the past 30 years, largely 
as a result of legislative pressures on specific sectors to end testing and/or use 
alternatives. There are now alternatives for a significant proportion of the stan­
dard "battery" of animal tests, which are typically required to test the safety 
of new chemicals and drugs. Unfortunately, the corresponding removal of the 
animal tests that these new alternatives replace is still forthcoming. There are 
many reasons why animal testing persists even, when there are alternatives, 
which have little to do with the scientific limitations of the new tests. Human 
limitations, including bureaucracy, political malaise, and entrenchment in the 
scientific establishment are as great, if not greater, barriers to the replacement 
of animals in testing. 
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There needs to be a paradigm change in the way science approaches many 
of its questions. The classic approach of test your idea or substance in a simple 
model, such as a cell culture; and then if successful test it in a more complex mod­
el, such as an animal, needs to change. Funding bodies and journals need to 
stop requiring proof of concept in animal models but in more human-relevant 
approaches. A more mechanistic approach is one possible way to facilitate the 
use of alternatives. Breaking down the question you need to answer into ques­
tions that can be tested in simpler models would facilitate a speedier uptake of 
alternatives. Another approach is to employ technology to overcome some of 
the current problems of using humans ethically or to increase the complexity 
of cell-based systems. Whether these two approaches will complete or comple­
ment each other remains to be seen. 
What will encourage science to change its paradigm? Political will needs 
to be amplified and targets for a reduction of animal experiments are needed. 
This, in tum, will help increase levels of funding to speed up the development 
of new approaches and reduce regulatory malaise, so that they are implement­
ed as soon as they appear. 
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